Jeet Uppal serves as the Senior Director of Customer & Market Insights for the Hematology/CAR-T division at Bristol Myers Squibb (BMS), where he plays a pivotal role in shaping the strategic direction of innovative therapies in the rapidly evolving field of cell therapy. With a...
Jeet Uppal serves as the Senior Director of Customer & Market Insights for the Hematology/CAR-T division at Bristol Myers Squibb (BMS), where he plays a pivotal role in shaping the strategic direction of innovative therapies in the rapidly evolving field of cell therapy. With a wealth of experience in global market insights and research strategy, Jeet leads a dynamic team dedicated to generating actionable insights that inform product launch decisions and drive the success of early development assets within the Hematology Franchise. His expertise is particularly evident in his leadership of the successful launches of Breyanzi and Abecma, two groundbreaking cell therapies designed to treat diffuse large B-cell lymphoma (DLBCL) and multiple myeloma, respectively.
In his current role, Jeet is responsible for overseeing all elements of global launch readiness, ensuring that the insights gathered translate into effective market strategies that resonate with healthcare providers and patients alike. His comprehensive understanding of market research methodologies and strategic planning enables him to navigate complex market dynamics and identify growth opportunities within the hematology sector. Jeet’s skills in brand management and product innovation are instrumental in positioning BMS as a leader in cell therapy, while his negotiation and direct marketing expertise facilitate strong partnerships and collaborations across the industry.
Jeet's multifaceted background, which spans various sectors including pharmaceuticals, animal health, and consumer goods, equips him with a unique perspective on market trends and consumer behavior. His commitment to building leadership teams and fostering a culture of insight-driven decision-making continues to propel BMS's mission of delivering transformative therapies to patients worldwide.
